Phase II study of high-dose epirubicin in non-small cell lung cancer.
24 patients with measurable advanced non-small cell lung cancer (NSCLC) were treated with epirubicin 135-150 mg/m2 every 3 weeks. There were 6 partial responses. Randomised studies should reveal whether and how incorporation of epirubicin into combination chemotherapy can enhance outcome in advanced NSCLC.
Wils
J
J
Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
Utama
I
I
Sala
L
L
Smeets
J
J
Riva
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D015251:Epirubicin